A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer.

ABSTRACT: Observational studies have demonstrated a decreased incidence of cancers among users of HMG CoA reductase inhibitors (statins) and a reduced risk of recurrence among statin users diagnosed with early stage breast cancer. We initiated a prospective study to identify potential biomarkers of simvastatin chemopreventive activity that can be validated in future trials. The contralateral breast of women with a previous history of breast cancer was used as a high-risk model. Eligible women who had completed all planned treatment of a prior stage 0-III breast cancer received simvastatin 40 mg orally daily for 24-28 weeks. At baseline and end-of-study, we measured circulating concentrations of high-sensitivity C-reactive protein (hsCRP), estrogens, and fasting lipids; breast density on contralatera

SUBMITTER: Higgins MJ 

PROVIDER: S-EPMC3536477 | biostudies-literature | 2012 Feb

REPOSITORIES: biostudies-literature